The Latest
-
Permission granted by Intellia Therapeutics
Gene editingIntellia CRISPR drug succeeds in late-stage study against rare swelling disorder
The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.
-
Getty Images
News roundupFDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.
-
Permission granted by Ajax Therapeutics
Lilly to buy startup Ajax in bid for a better JAK drug
Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Hemab Therapeutics, Seaport Therapeutics and Avalyn Pharma are poised to price offerings in what could be the sector’s busiest week for IPOs since early February.
Updated April 27, 2026 -
Getty Images
Oruka surges as long-acting psoriasis drug shows early promise
A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.
-
Courtesy of Sanofi
Sanofi MS drug rejected in US gets an endorsement in Europe
Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions the therapy for its first regulatory approval.
-
Permission granted by Roche
Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.
-
Getty Images
FDA approves Regeneron’s hearing loss gene therapy
Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher program and will be offered to eligible patients at no cost.
-
Getty Images
News roundup
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.
Updated April 24, 2026 -
Getty Images
Sanofi posts upbeat sales as R&D pressure builds
A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But positive first-quarter earnings provided the company with a needed boost.
-
Permission granted by Hwang lab
Revolution drug shows promise in early pancreatic cancer
The findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and generate billions in sales.
-
Getty Images
An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma?
A new tool is giving researchers a “data center full of genius Ph.D. students in their pocket.”
-
Maddie Meyer via Getty Images
VaccinesModerna, after losing US funding, rebounds to start mRNA bird flu vaccine trial
A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
Lilly’s acquisition of Ajax was the third biopharma buyout announced since Sunday night, following Sun Pharma’s purchase of Organon and Ligand Pharmaceuticals’ deal for Xoma Royalty.
Updated April 27, 2026 -
Getty Images
News roundup
Merck adds to pharma’s AI push; Roche details MS drug results
Merck is making a $1 billion investment in a deal with Google Cloud. Elsewhere, Roche pitched its case for a closely watched multiple sclerosis pill and Arcus and Gilead are ending a yearslong alliance.
-
Permission granted by Serif Biosciences
Startup launchesSerif, Flagship’s latest biotech, aims to make a new kind of genetic medicine
The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy.
-
Getty Images
AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
Featured at this year’s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and several targeted medicines for lung tumors.
-
Getty Images
Brain drug revivalTrump executive order lifts psychedelics biotechs
Meant to speed research and access to psychedelics for mental health conditions, the order is the latest in a series of developments that, to Wall Street, make psychedelics a more “investable space.”
-
Courtesy of Merck & Co.
Merck’s fast-ascending kidney cancer drug hits a setback
Welireg’s failure in first-line kidney cancer removes a blockbuster opportunity and could leave an opening for a rival drug from Arcus Biosciences, analysts said.
-
Permission granted by Tortugas Neuroscience
Startup launchesTortugas debuts with $106M and brain drugs from Hansoh, Eisai
Led by former Sage Therapeutics executives Jeff Jonas and Al Robichaud, the company is starting out with a portfolio of neurological medicines in clinical testing.
-
Getty Images
Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout
Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s currently in early-stage testing for multiple myeloma.
-
Getty Images
Nektar surges again as alopecia drug shows new promise in extension study
Patients who'd seen substantial hair regrowth in the first part of Nektar’s trial had a "deepening" treatment response, extending a comeback bid that’s caused shares to skyrocket over the last year.
-
Getty Images
BioAge says early data suggest ‘best-in-class’ potential for inflammation drug
The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an inflammasome linked to a variety of health conditions.
-
Heather Diehl/Getty Images via Getty Images
Trump administrationRFK Jr. defends HHS tenure, 12% proposed budget cut
Republicans largely praised the HHS secretary’s track record during a marathon of House hearings last week, but some raised concerns about proposed budget cuts to the National Institutes of Health.
-
Courtesy of EQT Life Sciences
Brain drug revivalUCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B
The acquisition helps diversify UCB’s small molecule-centric arsenal of seizure treatments with a potentially one-off therapy in early testing for a hard-to-treat form of a common epilepsy.
